<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04157478</url>
  </required_header>
  <id_info>
    <org_study_id>GXPH-19001</org_study_id>
    <nct_id>NCT04157478</nct_id>
  </id_info>
  <brief_title>Addition of Anlotinib Hydrochloride to the Stupp Regimen Versus the Stupp Regimen Alone for Newly Diagnosed Glioblastoma</brief_title>
  <official_title>Addition of Anlotinib Hydrochloride to the Stupp Regimen Versus the Stupp Regimen Alone for Newly Diagnosed Glioblastoma: A Randomized Multicenter Prospective Phase II Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>People's Hospital of Guangxi</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>First Affiliated Hospital of Guangxi Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cancer Hospital of Guangxi Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Liuzhou Worker's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Nanxishan Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>LiuZhou People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Affiliated Hospital of Guilin University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>People's Hospital of Guangxi</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      For patients with glioblastoma,postoperative radiotherapy combined with concurrent and
      adjuvant temozolomide (Stupp regimen) has long been considered a standard treatment
      approach.The treatment outcomes, however, are still dismal, with a median overall survival
      time of 8-12 months. As a novel small molecule multi-target tyrosine kinase inhibitor,
      anlotinib hydrochloride has been found to be able to inhibit both tumor angiogenesis and cell
      growth.Previous studies on recurrent glioblastoma have demonstrated its effectiveness in
      tumor control with manageable toxicities. The current study is designed to evaluate the
      efficacy and feasibility of the additional anlotinib hydrochloride to the Stupp regimen for
      newly diagnosed glioblastoma.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 2020</start_date>
  <completion_date type="Anticipated">December 2024</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response rate</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">464</enrollment>
  <condition>Glioblastoma</condition>
  <arm_group>
    <arm_group_label>Radiation therapy, Temozolomide and anlotinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive standard radiation therapy plus temozolomide (Stupp regimen). Anlotinib hydrochloride will be given with a daily dose of 12 mg for 14 days of a 21-day cycle up to 2 cycles, initiated on the first day of radiation therapy and followed by adjuvant treatment with the same dosing schedule until patients have disease progression or intolerable toxicities.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Radiation therapy and temozolomide</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will receive standard radiation therapy plus temozolomide (Stupp regimen).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anlotinib Hydrochloride</intervention_name>
    <description>Anlotinib hydrochloride will be given with a daily dose of 12 mg for 14 days of a 21-day cycle up to 2 cycles, initiated on the first day of radiation therapy and followed by adjuvant treatment with the same dosing schedule until patients have disease progression or intolerable toxicities.</description>
    <arm_group_label>Radiation therapy, Temozolomide and anlotinib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiation therapy</intervention_name>
    <description>Radiation therapy will be delivered in daily fractions of 2 Gy given 5 days a week for a total of 60 Gy.</description>
    <arm_group_label>Radiation therapy and temozolomide</arm_group_label>
    <arm_group_label>Radiation therapy, Temozolomide and anlotinib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Temozolomide</intervention_name>
    <description>Temozolomide will be administered at a daily dose of 75 mg/m2 until the completion of radiation therapy. Four weeks after the completion of radiation therapy, patients will be given with adjuvant chemotherapy with temozolomide at a dose of 150-200 mg/m2 for 5 days of a 28-day cycle for a total of 6 cycles.</description>
    <arm_group_label>Radiation therapy and temozolomide</arm_group_label>
    <arm_group_label>Radiation therapy, Temozolomide and anlotinib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Newly diagnosed and histological proven glioblastoma

          -  Complete gross resection or subtotal resection

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0-2

          -  Adequate bone marrow, liver and renal function

          -  Written informed consent

        Exclusion Criteria:

          -  Meningeal carcinomatosis or spinal compression

          -  Patients who have previously received chemotherapy, targeted therapy, or
             anti-angiogenesis

          -  Active, known, or suspected autoimmune disease

          -  Severe allergy to anlotinib or temozolomide

          -  Patient having acute hepatitis virus infection, active tuberculosis, or other acute
             infectious diseases

          -  Uncontrolled mental disorders

          -  High risk of bleeding

          -  Severe cardiovascular disease: myocardial ischemia or myocardial infarction above
             grade II, poorly controlled arrhythmias (including men with QTc interval ≥ 450 ms,
             women ≥ 470 ms), according to NYHA criteria; grades III to IV Insufficient function,
             or cardiac color Doppler ultrasound examination indicates left ventricular ejection
             fraction (LVEF) &lt;50%

          -  Contraindicated for MRI examination

          -  Recipient of live vaccine prior to the first dose of anlotinib

          -  Ready for or previously received organ transplantation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Heming Lu, MD</last_name>
    <phone>86-771-2186-504</phone>
    <email>gxheminglu@sina.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Nanxishan Hospital of Guangxi Zhuang Autonomous Region</name>
      <address>
        <city>Guilin</city>
        <state>Guangxi</state>
        <zip>541002</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Liuzhou Worker's Hospital</name>
      <address>
        <city>Liuzhou</city>
        <state>Guangxi</state>
        <zip>545005</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Liuzhou People's Hospital</name>
      <address>
        <city>Liuzhou</city>
        <state>Guangxi</state>
        <zip>545006</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Affiliated Hospital of Guangxi Medical University</name>
      <address>
        <city>Nanning</city>
        <state>Guangxi</state>
        <zip>530021</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Affiliated Tumor Hospital of Guangxi Medical University</name>
      <address>
        <city>Nanning</city>
        <state>Guangxi</state>
        <zip>530021</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>People's Hospital of Guangxi Zhuang Autonomous Region</name>
      <address>
        <city>Nanning</city>
        <state>Guangxi</state>
        <zip>530021</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Heming Lu, MD</last_name>
      <phone>+86-771-218-6503</phone>
      <email>gxheminglu@sina.com</email>
    </contact>
    <investigator>
      <last_name>Heming Lu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Yulin First Hospital</name>
      <address>
        <city>Yulin</city>
        <state>Guangxi</state>
        <zip>537000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>November 6, 2019</study_first_submitted>
  <study_first_submitted_qc>November 6, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 8, 2019</study_first_posted>
  <last_update_submitted>November 7, 2019</last_update_submitted>
  <last_update_submitted_qc>November 7, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 12, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>People's Hospital of Guangxi</investigator_affiliation>
    <investigator_full_name>Heming Lu</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Glioblastoma</keyword>
  <keyword>Anlotinib hydrochloride</keyword>
  <keyword>Stupp regimen</keyword>
  <keyword>Temozolomide</keyword>
  <keyword>Radiation therapy</keyword>
  <keyword>Tyrosine kinase inhibitor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioblastoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Temozolomide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

